

## **Combined treatment of condilomata accuminata Yusupova Sh.A.**

Basic doctoral student of Tashkent medical academy

**Objectives:** In comparison to other genital wart treatment options, Imiquimod is an immune response modulator with excellent competence and relatively low recurrence rates. This study's main goal was to assess how laser treatment for external anogenital warts affected the continued clearance of treated lesions and the safety of topical Imiquimod used by the patient.

**Methods:** Asses 2 type of treatment: monotherapy by laser with combined therapy - after laser treatment of visible external anogenital warts, the ablated region(s) were treated with Imiquimod 5% cream, in the following order: three times per week over the course of 12 weeks, starting once when the wound healing process was considered complete, followed by a six-month observation period for the assessment of sustained clearance of treated lesions.

**Results:** 28 (37.3%) of the patients in the first group experienced relapses during the course of the study, according to a correlative assessment of the clinical competence of the treatment. The recurrence rate within 6 months was only 9 (7.2%) and clinical recovery without a recurrence was 116 (92.8%) in group II patients, which is a statistically significant ( $p \leq 0.05$ ) reduction in the relapse rate with the complex method therapy.

**Conclusions:** Administration of Imiquimod 5% cream three times per week seems to be safe and to lower the likelihood of wart recurrences after laser therapy and adequate wound healing.

**Keywords:** condylomata acuminata, immune response modifier, recurrences

Human papillomavirus (HPV) anogenital infections are the most prevalent viral sexually transmitted disease (STD) among young people worldwide. Treatments that have demonstrated good to moderate efficacy in eliminating genital warts include patient-applied topical medications (podophyllotoxin, interferon (IFN)), as well as ablative or cytotoxic techniques [1,2]. Due to anesthesia or many therapeutic interventions required to completely eliminate the wart region, the majority of ablative therapy techniques have the potential to be uncomfortable and painful for the patient. Yet, the high rate of wart recurrences after effective first treatment is thought to be the most source of frustration. The recorded recurrence rates for ablative techniques range from 20% with surgical excision to 50% with alternative destructive therapies. The lack of antiviral action with the majority of the suggested therapy is one theory for the recurrent recurrence of warts. As a result, only the wart itself is physically eliminated, leaving the surrounding tissue still harboring latent HPV that could reactivate[3,4].

Since Imiquimod is known to generate many subtypes of IFN- $\alpha$  and IFN- $\gamma$  as well as a variety of cytokines linked to Th1-cell-mediated immunity, it is a more comprehensive and natural approach. The first member of a novel class of immune response modifiers with significant antiviral and anticancer action is Imiquimod, an imidazoquinolinamine derivate [5,6]. It has been demonstrated that Imiquimod 5%

cream, used three times per week for a maximum of 16 weeks, is both extremely effective and secure for use in the primary treatment of external genital warts [7-9]. In one research, with three weekly doses and a 12-week treatment-free follow-up period, the recurrence rate was as low as 13% [8]. Recurrence rates following wart ablation may be lowered by adjuvant IFN therapy, which would also improve the patient's resistance to viral infections. The majority of study findings, however, did not consistently demonstrate the advantages of combination therapy [10]. This clinical trial examined whether the incidence of recurring warts following laser therapy may be decreased by using laser therapy followed by Imiquimod 5% cream for 4–16 weeks.

### **Methods.**

Researchers (n=200) were chosen from the university's laser dermatovenerology department. The main goal of the study was to analyze the efficacy and sustained clearance of anogenital warts following laser treatment as a monotherapy and combined therapy [laser+Imiquimod] as determined by clinical visual examination.

#### **Patients**

The trial was open to female patients with external anogenital warts aged 16 to 50. Patients were not eligible for the study if they had previously received Imiquimod, IFN, IFN-inducers, immunomodulators, oral antiviral medications (aside from oral acyclovir for suppressive or acute therapy), topical antiviral medications applied to the wart site, cytotoxic medications, other investigational medications, drugs known to have major organ toxicity, chemical and/or surgical wart therapy within four weeks of enrolling in the study, or any combination of these treatments (within two weeks of initiation visit). Also, patients with inflammatory skin disorders or those who required concurrent topical medication in the wart location were excluded, as were women who were expecting or nursing.

The patients were split into two groups to study the efficacy of the revised therapeutic strategy. 75 women made up the first patient group, to whom we utilized the Lutronic CO2 laser technology for genital wart eradication. The technique enables layer-by-layer removal of the tumor along with the underlying stroma, which is not possible with straightforward surgical excision. We performed continuous CO2-laser vaporization of vulvar condylomas using the high-intensity laser surgical tool "Lutronic" with a radiation output of 16–20 W and a destruction depth of 0.3–0.7 cm.

The patients in both groups received wound care with Betadine solution 4-6 times starting on the first day following the damaging therapy, until a crust developed within 14 days.

The second group of patients included 125 women who had combination therapy with the 5% local cream "Imiquimod" after having their genital warts removed by laser. Starting on the fourteenth day following the destruction, the patients in the main group received a single application of the 5% cream "Imiquimod" in the amount of 3g per use on the affected area, nearby tissues, and the area around the anus. This treatment was given every other day for 12 hours for 4–12 weeks. After 1, 3, and 6 months after destruction, observations of patients were

conducted, and it was noted that there had been no relapse or reinfection. We declared a clinical recovery based on the clinical evidence and the absence of new genital warts.

**Table No. 1. Some parameters of patients who participated in the study.**

<b>№</b>	<b>Patient Selection Criteria</b>	<b>Number of patients participating in the study (n=200)</b>
1.	<b>Sex</b>	
	Women	100% (200)
2.	Age (16-50)	29,6±7,4
3.	Pregnancy	-
4.	<b>HPV screening titer 12 types</b>	
	HPV DNA A5A6 (types 51,56)	3
	HPV DNA A7 (types 18,39,45,59)	5
	HPV A9 DNA (types 16,31,33,35,52,58)	8
5	<b>Number of partners</b>	
	1	115
	2	47
	3 and more	38
6	<b>Localization</b>	
	In the area of the labia	70
	In the urethra, vagina and cervix	90
	in the perianal region	40
7	<b>Clinical forms</b>	
	Macular lesions	8
	Papular warts	23
	Condyloma acuminata	169

Regarding sex, age, and the severity of the diseased process, both patient groups were comparable. In our study, 200 individuals underwent laser ablation. The number of patients with no recurrence of vulvar genital warts during the 6-month follow-up period, as well as the significance of differences between groups in the frequency of genital wart recurrence using the Chi<sup>2</sup> test and Fisher's exact test, were used to evaluate the efficacy of the methods we used. The follow-up period was completed by 200 patients in total. We examined the frequency of vaginal wart recurrence in patients 6 months after the commencement of treatment in order to evaluate the efficacy of the prescribed treatment over the course of this study. The existence of at least one development in the region of the external genital organs was the requirement for recurrence.

## RESULTS

### Comparative evaluation of clinical efficacy of treatment.

<b>Following period</b>	<b>I group n-75</b>		<b>II group n-125</b>		<b>p</b>
	<b>abs.</b>	<b>%</b>	<b>abs.</b>	<b>%</b>	

<b>1<sup>st</sup> month</b>	12	16	6	4.8	p≤0.05
<b>3<sup>rd</sup> month</b>	9	12	3	2.4	p≤0.05
<b>6<sup>th</sup> month</b>	7	9.3	0	0	p≤0.05

In a comparative evaluation of the efficacy of treatment for external genital warts in the anogenital region for six months, it was determined that: after one month, the best clinical effect was detected when using a complex method of treatment; only six patients (4.8%) experienced new genital warts during examination and vulvoscopy, which was significantly less than the control group's twelve (16%) cases. In group I, 9 (12%) patients demonstrated an aggravation of the condition in the form of the formation of new clinical foci after a 3-month follow-up period, while group II had a recurrence rate of 3 (2.4%) during the same time frame. Seven (9.3%) of the group I patients experienced relapses at the conclusion of the observation period (6 months), whereas there was no relapse in the group II, demonstrating the efficacy of a complicated treatment regimen for genital warts. The presented data shows that the frequency of genital wart recurrence was statistically substantially ( $p \leq 0.05$ ) lower with a complicated way of therapy than with laser monotherapy.

**Table No. 3. Total number of relapses during the observation period.**

	<b>I group n-75</b>		<b>II group n-125</b>		<b>p</b>	<b>Chi<sup>2</sup></b>	<b>RR</b>	<b>95% CI(C)</b>
	<b>abs.</b>	<b>%</b>	<b>abs.</b>	<b>%</b>				
<b>Total number of relapses</b>	28	37.3	9	7.2%	p≤0,001	28.230	2.624	1.939 - 3.552
<b>Absence of relapse</b>	47	62.7	116	94.4				

According to the study, sophisticated methods of therapy are a rather successful way to cure external genital warts in the anogenital region. A comparison of the clinical efficacy of the treatments revealed that 28 (37.3%) of the first group's patients experienced relapses throughout the entire observation period. The recurrence rate within 6 months was only 9 (7.2%) and clinical recovery without a recurrence was 116 (92.8%) in group II patients, which is a statistically significant ( $p \leq 0.05$ ) reduction in the relapse rate with the complex method therapy.

There were no documented severe adverse medication reactions. A few instances of systemic symptoms like fever or myalgia were observed, although local skin reactions at the treatment site were the most often reported adverse event. The most frequent side effects, which affected more than 80% of all patients, were skin diseases in the areas where the warts were treated, including burning, itching, pain, and redness. Generally, they were easily tolerated and went away quickly once the dosage was lowered or a break was taken.

Hence, using a combined approach to treat genital warts is a better technique of treatment since it allows for deeper penetration of the local 5% Imiquimod cream, which is where this medication's immunomodulatory properties are active, by reducing hyperkeratosis through laser vaporization. In turn, this cream affects the

lesion's site-specific clinical and subclinical HPV forms, which cannot be treated by laser light. This result implies that these two approaches complement one another and lower the recurrence rate.

## DISCUSSION

Recurrence rates after laser therapy for genital warts are vary, according to data from the literature, and they tend to happen more often around the edges of previously ablated areas. It has been suggested that the outcome could be enhanced by extending the ablation to surrounding, clinically unaffected regions that carry latent HPV beyond the apparent lesion. Immune response modifiers allow for an alternative strategy by improving the cutaneous antiviral immune response. The outcomes of this open-label, prospective study show that Imiquimod 5% cream, an adjuvant topical immunomodulatory medication, can prolong the effects of laser therapy for external genital warts. In this study, laser therapy combined with Imiquimod 5% cream produced better benefits than laser therapy alone as reported in the literature.

The local cellular immune response is activated by adjuvant Imiquimod 5% cream treatment, and this response is principally mediated by the stimulation of specific pro-inflammatory and antiviral cytokines, primarily IFN- $\alpha$ , tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), and various interleukines (e.g. IL-6, -8, -10, -12). A molecular investigation with HPV-infected patients<sup>7</sup> has shown the mechanism of action in HPV-related genital warts. Changes in the tissue levels of these cytokines and a considerable drop in viral load, as indicated by tissue levels of E7-mRNA and capsid protein L1-mRNA, were directly associated with wart regression. Most intriguingly, one trial participant who received placebo also completely cleared his warts, and the alterations in immunological markers that were observed in this participant were very identical to those in the patients who received Imiquimod. Similar to the immunological process that takes place during spontaneous regression, this improvement in the local immune response also has a long-term effect on cutaneous HPV-infections, preventing recurrences and new infections with the same HPV type or subtype.

The combined ablative/adjuvant treatment was typically highly well-liked by patients who remained in the research for the entire course of treatment. This is possibly due to the medication's low recurrence rate in comparison to prior experiences, improved tolerability, and straightforward, self-administered pharmacological therapy. On the other hand, the high drop out rate is one of the most significant problems with this study and is most likely caused by patients' unwillingness to adhere to a three-month medical treatment plan after their lesions had been completely removed and no clinically obvious genital warts were present. Patients should receive full instructions on following the suggested treatment schedule and administering the medicine just to the area involved, including the margins of the ablated area, in order to ensure that they benefit from the therapeutic operation.

The results of this study clearly show that topical Imiquimod 5% cream treatment for 12 weeks after laser treatment of genital warts is safe and appears to be

an effective therapeutic approach to reduce the incidence of wart recurrences, which is one of the least desirable aspects of conventional treatment modalities.

## LITERATURE

1. Woodby B, Scott M, Bodily J. The Interaction Between Human Papillomaviruses and the Stromal Microenvironment. *Progress in Molecular Biology and Translational Science*. 2016;144:169-238. DOI: <https://doi.org/10.1016/bs.pmbts.2016.09.003>
2. Xiao Yang, Yanxiang Cheng, Chunsheng Li. The role of TLRs in cervical cancer with HPV infection: a review. *Signal Transduction and Targeted Therapy* 2017; 2: e17055. DOI: 10.1038/sigtrans.2017.55
3. Xu H, Shen Q, Fan B, Xi C, a combination therapy of traditional Chinese medicine and CO laser treatment for condyloma acuminatum. *Journal of medical virology*. 2020. Online ahead of print.
4. Yuan H, Krawczyk E, Blancato J, Albanese C, Zhou D, Wang N, et al. HPV positive neuroendocrine cervical cancer cells are dependent on Myc but not E6/E7 viral oncogenes. *Scientific Reports*. 2017;7:45617.
5. Zeng Y, Hesketh T. The effects of China's universal two-child policy. *Lancet*. 2016;388:1930- 1938.
6. Zeng Y.Y, Chen XY, Tian KG, et al. The correlation of interleukin-10 gene polymorphism and HPV infection and cervical lesions in Dongguan region. *Journal of Clinical and Experimental Medicine*. 2015;14:636-639.
7. Wesselmann P, Schwarze-Zander C, Boesecke C, et al. HPV-associated anal lesions in HIV+ patients: long-term results regarding quality of life. *Int J Colorectal Dis*. 2020;35(6):1103-1110. doi:10.1007/s00384-020-03567-1
8. Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. *Virus research*. 2017; 231:21-33.
9. Wiraguna AAGP, Andriani PI, Adiguna MS. Comparison of Plasma Zinc Levels Among HIV+ and HIV- Subjects Infected with Condyloma Acuminata. *Asian Pac J Cancer Prev*. 2019;20(3):943-949. Published 2019 Mar 26. doi:10.31557/APJCP.2019.20.3.943
10. Wojcinski M. 14 Jahre HPV-Impfung: was haben wir erreicht? [14 years of HPV vaccination: what has been achieved?]. *Gynakologe*. 2021;54(11):801-809. doi:10.1007/s00129-021-04869-3